A fusion peptide comprising a first peptide linked to a second peptide, which first peptide comprises the sequence: X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 wherein X 1 is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β hydroxy-histidine, homohistidine, N α -acetyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine; X 2 is A, G, V, L, I, K, S, aminoisobutyric acid (Aib), (1-aminocyclopropyl) carboxylic acid, (1 aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1 aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid; X 3 is E, D or Q; X 4 is G or A; X 5 is T, V, S or I; X 6 is F or Y; X 7 is T, or S; X 8 is S, V, or D; X 9 is S, D, E, N or is not present, or the first peptide comprising the sequence laid out in SEQ ID NO: 40 or SEQ ID NO: 41 or SEQ ID NO: 42, and which second peptide has an amino acid sequence with at least 70% identity with any one of SEQ ID NO:24 to SEQ ID NO:31, or wherein the second peptide is selected from the list consisting of: X 10 -X 11 -P-X 12 -I-L; P-X 10 -X 11 -P-X 12 -I-L; K-P-X 10 -X 11 -P-X 12 -I-L; N-K-P-X 10 -X 11 -P-X 12 -I-L; E-N-K-P-X 10 -X 11 -P-X 12 -I-L; Y-E-N-K-P-X 10 -X 11 -P-X 12 -I-L; L-Y-E-N-K-P-X 10 -X 11 -P-X 12 -I-L; Q-L-V-E-N-K-P-X 10 -X 11 -P-X 12 -I-L; or E-L-Y-E-N-K-P-X 10 -X 11 -P-X 12 -I-L wherein X 10 is R or K; X 11 is R or K; and X 12 is Y, S, C or T, and wherein the fusion peptide is a dual agonist of both a glucagon like peptide 1 receptor and a neurotensin receptor. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 wherein X 1 is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β hydroxy-histidine, homohistidine, N α -acetyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine; X 2 is A, G, V, L, I, K, S, aminoisobutyric acid (Aib), (1-aminocyclopropyl) carboxylic acid, (1 aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1 aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid; X 3 is E, D or Q; X 4 is G or A; X 5 is T, V, S or I; X 6 is F or Y; X 7 is T, or S; X 8 is S, V, or D; X 9 is S, D, E, N or is not present, or the first peptide comprising the sequence laid out in SEQ ID NO: 40 or SEQ ID NO: 41 or SEQ ID NO: 42, and which second peptide has an amino acid sequence with at least 70% identity with any one of SEQ ID NO:24 to SEQ ID NO:31, or wherein the second peptide is selected from the list consisting of: X 10 -X 11 -P-X 12 -I-L; P-X 10 -X 11 -P-X 12 -I-L; K-P-X 10 -X 11 -P-X 12 -I-L; N-K-P-X 10 -X 11 -P-X 12 -I-L; E-N-K-P-X 10 -X 11 -P-X 12 -I-L; Y-E-N-K-P-X 10 -X 11 -P-X 12 -I-L; L-Y-E-N-K-P-X 10 -X 11 -P-X 12 -I-L; Q-L-V-E-N-K-P-X 10 -X 11 -P-X 12 -I-L; or E-L-Y-E-N-K-P-X 10 -X 11 -P-X 12 -I-L wherein X 10 is R or K; X 11 is R or K; and X 12 is Y, S, C or T, and wherein the fusion peptide is a dual agonist of both a glucagon like peptide 1 receptor and a neurotensin receptor. X 10 -X 11 -P-X 12 -I-L; P-X 10 -X 11 -P-X 12 -I-L; K-P-X 10 -X 11 -P-X 12 -I-L; N-K-P-X 10 -X 11 -P-X 12 -I-L; E-N-K-P-X 10 -X 11 -P-X 12 -I-L; Y-E-N-K-P-X 10 -X 11 -P-X 12 -I-L; L-Y-E-N-K-P-X 10 -X 11 -P-X 12 -I-L; Q-L-V-E-N-K-P-X 10 -X 11 -P-X 12 -I-L; or E-L-Y-E-N-K-P-X 10 -X 11 -P-X 12 -I-L wherein X 10 is R or K; X 11 is R or K; and X 12 is Y, S, C or T, and wherein the fusion peptide is a dual agonist of both a glucagon like peptide 1 receptor and a neurotensin receptor.